Immune checkpoint inhibitors (ICIs) targeting immune checkpoints, such as the interaction of programmed cell death 1 (PD-1) and programmed cell death-ligand 1 (PD-L1), have been widely used in various solid cancers and have achieved impressive success in cancer treatment, leading to a new era of anticancer therapy. Here, PDCD1 is linked to cancer.